In a first of its kind, the @fda.gov has approved the first mesenchymal stem cell therapy, Mesoblast’s Ryoncil for the treatment of graft versus host disease.
In landmark, FDA approves first MSC therapy, Mesoblast's Ryoncil for GvHD - The Niche
Professor discusses FDA approval of first MSC therapy, Mesoblast's Ryoncil for GvHD, a milestone for the field.
ipscell.com
December 25, 2024 at 3:59 PM
In a first of its kind, the @fda.gov has approved the first mesenchymal stem cell therapy, Mesoblast’s Ryoncil for the treatment of graft versus host disease.
#$MESO received FDA approval for a new TIBA assay to check strength and stability of every commercial Ryoncil batch as manufacturing scales. notreload.xyz/xy/mesoblast...
Mesoblast Gets FDA OK for Ryoncil Strength Assay
Mesoblast received FDA approval for a new TIBA assay to check strength and stability of every commercial Ryoncil batch as manufacturing scales.
notreload.xyz
September 24, 2026 at 11:42 AM
#$MESO received FDA approval for a new TIBA assay to check strength and stability of every commercial Ryoncil batch as manufacturing scales. notreload.xyz/xy/mesoblast...
Perspectives: In landmark decision, FDA approves first MSC therapy, Mesoblast's Ryoncil for GvHD ipscell.com/2024/12/in-l... #stemcells #stemcell
In landmark, FDA approves first MSC therapy, Mesoblast's Ryoncil for GvHD - The Niche
Professor discusses FDA approval of first MSC therapy, Mesoblast's Ryoncil for GvHD, a milestone for the field.
ipscell.com
December 18, 2024 at 11:41 PM
Perspectives: In landmark decision, FDA approves first MSC therapy, Mesoblast's Ryoncil for GvHD ipscell.com/2024/12/in-l... #stemcells #stemcell
Massive achievement for the MSC therapy field! Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months...
www.globenewswire.com
December 19, 2024 at 7:59 AM
Massive achievement for the MSC therapy field! Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Yesterday, #Ryoncil became the first FDA-approved mesenchymal stromal #celltherapy indicated to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients who are two months and older. #stemcells www.fda.gov/news-events/...
FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease
FDA approves Ryoncil, the first MSC therapy to treat steroid-refractory acute graft-versus-host disease (SR-a GVHD) in pediatric patients 2 months of age and ol
www.fda.gov
December 19, 2024 at 6:32 PM
Yesterday, #Ryoncil became the first FDA-approved mesenchymal stromal #celltherapy indicated to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients who are two months and older. #stemcells www.fda.gov/news-events/...
Congratulations to Mesoblast!
👏🏻👏🏻👏🏻
First MSC product to gain FDA approval. 🎉
www.fda.gov/drugs/resour...
👏🏻👏🏻👏🏻
First MSC product to gain FDA approval. 🎉
www.fda.gov/drugs/resour...
FDA approves remestemcel-L-rknd for steroid-refractory acute graft ver
On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-ref...
www.fda.gov
December 19, 2024 at 3:07 AM
Congratulations to Mesoblast!
👏🏻👏🏻👏🏻
First MSC product to gain FDA approval. 🎉
www.fda.gov/drugs/resour...
👏🏻👏🏻👏🏻
First MSC product to gain FDA approval. 🎉
www.fda.gov/drugs/resour...
Fantastic to see Mesoblast's MSC cell therapy product finally approved for pediatric aGVHD.
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months...
www.globenewswire.com
December 19, 2024 at 8:08 AM
Fantastic to see Mesoblast's MSC cell therapy product finally approved for pediatric aGVHD.
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Our International Society of Cell & Gene Therapy @isctglobal.bsky.social MSC committee has published this statement on the US FDA approval of allogenic Bone Marrow- derived mesenchymal stem/stromal cells. www.sciencedirect.com/science/arti...
ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)—allogeneic bone marrow mesenchymal stroma…
www.sciencedirect.com
February 4, 2025 at 12:00 PM
Our International Society of Cell & Gene Therapy @isctglobal.bsky.social MSC committee has published this statement on the US FDA approval of allogenic Bone Marrow- derived mesenchymal stem/stromal cells. www.sciencedirect.com/science/arti...
Is Ryoncil the last #CGT product to gain FDA approval in 2024 or is there one more surprise to come? www.biospace.com/fda/mesoblas...
Mesoblast Wins First Mesenchymal Stromal Cell Therapy FDA Approval for GVHD
The approval concludes what has been a difficult regulatory path for Ryoncil, which suffered FDA rejections in 2020 and 2023.
www.biospace.com
December 23, 2024 at 6:12 PM
Is Ryoncil the last #CGT product to gain FDA approval in 2024 or is there one more surprise to come? www.biospace.com/fda/mesoblas...
A milestone for the therapeutic #EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal #cell therapy
www.oaepublish.com/articles/evc...
www.oaepublish.com/articles/evc...
A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy
Small extracellular vesicles (sEVs) derived from mesenchymal stromal cells (MSCs) hold substantial promise for therapeutic applications, including immune modulation and tissue regeneration. However, c...
www.oaepublish.com
March 25, 2025 at 6:48 PM
A milestone for the therapeutic #EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal #cell therapy
www.oaepublish.com/articles/evc...
www.oaepublish.com/articles/evc...
MESOBLAST Achieves First Ever U.S. FDA Approval of an MSC Therapy (RYONCIL®) - bioinformant.com/mesoblasts-f...
MESOBLAST Achieves First Ever U.S. FDA Approval of an MSC Therapy (RYONCIL®) | BioInformant
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. In a single-arm, multi-center, Phase 3 trial of children with steroids-refractory (SR) acute GvHD, 70% achieved an ...
bioinformant.com
January 12, 2025 at 4:12 AM
MESOBLAST Achieves First Ever U.S. FDA Approval of an MSC Therapy (RYONCIL®) - bioinformant.com/mesoblasts-f...
Perspectives: In landmark decision, FDA approves first MSC therapy, Mesoblast's Ryoncil for GvHD ipscell.com/2024/12/in-l... #stemcells #stemcell $MESO
In landmark, FDA approves first MSC therapy, Mesoblast's Ryoncil for GvHD - The Niche
Professor discusses FDA approval of first MSC therapy, Mesoblast's Ryoncil for GvHD, a milestone for the field.
ipscell.com
December 18, 2024 at 11:35 PM
Perspectives: In landmark decision, FDA approves first MSC therapy, Mesoblast's Ryoncil for GvHD ipscell.com/2024/12/in-l... #stemcells #stemcell $MESO
First FDA-Approved Mesenchymal Stromal Cell Therapy Marks a Major Advancement in Regenerative Medicine#United_States#New_York#Ryoncil#MSC#Osiris_Therapeutics
First FDA-Approved Mesenchymal Stromal Cell Therapy Marks a Major Advancement in Regenerative Medicine
The FDA has granted approval for RYONCIL®, the first therapy using mesenchymal stromal cells (MSCs) to treat children with a rare condition, marking a significant milestone for regenerative medicine.
third-news.com
January 16, 2025 at 5:49 PM
First FDA-Approved Mesenchymal Stromal Cell Therapy Marks a Major Advancement in Regenerative Medicine#United_States#New_York#Ryoncil#MSC#Osiris_Therapeutics
FDA approves a new mesenchymal stromal cell therapy for GVHD in pediatric SCT recipients.
COI—we are exploring the potential of other MSC-associated therapies in GVHD and other diseases.
www.fda.gov/drugs/resour...
COI—we are exploring the potential of other MSC-associated therapies in GVHD and other diseases.
www.fda.gov/drugs/resour...
FDA approves remestemcel-L-rknd for steroid-refractory acute graft ver
On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-ref...
www.fda.gov
December 19, 2024 at 4:11 AM
FDA approves a new mesenchymal stromal cell therapy for GVHD in pediatric SCT recipients.
COI—we are exploring the potential of other MSC-associated therapies in GVHD and other diseases.
www.fda.gov/drugs/resour...
COI—we are exploring the potential of other MSC-associated therapies in GVHD and other diseases.
www.fda.gov/drugs/resour...
Mesoblast's mesenchymal stem cell therapy receives FDA approval for children age 2 months + for steroid-refractory acute graft versus host disease.
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months...
www.globenewswire.com
December 19, 2024 at 5:50 AM
Mesoblast's mesenchymal stem cell therapy receives FDA approval for children age 2 months + for steroid-refractory acute graft versus host disease.
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Wow. FDA Approves 1st MSCTherapy. This one to treat GvHD. This is from Mesoblast. A milestone US approval www.fda.gov/news-events/... #stemcells #stemcell. One of my 2025 predictions I made yesterday came true a little early! ipscell.com/2024/12/25-s...
FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease
FDA approves Ryoncil, the first MSC therapy to treat steroid-refractory acute graft-versus-host disease (SR-a GVHD) in pediatric patients 2 months of age and ol
www.fda.gov
December 18, 2024 at 10:08 PM
Wow. FDA Approves 1st MSCTherapy. This one to treat GvHD. This is from Mesoblast. A milestone US approval www.fda.gov/news-events/... #stemcells #stemcell. One of my 2025 predictions I made yesterday came true a little early! ipscell.com/2024/12/25-s...
Mesoblast ( #MSB ) has released " FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval " on Thu 15 May at 10:01 AEST #today #China #UnitedStates #ClinicalTrials #Australia
Mesoblast share price
Mesoblast (ASX:MSB) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Mesoblast’s share price, chart, trading volume,
grafa.com
May 15, 2025 at 12:07 AM
Mesoblast ( #MSB ) has released " FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval " on Thu 15 May at 10:01 AEST #today #China #UnitedStates #ClinicalTrials #Australia
#biotecnología hoy:
🧬 $MESO Ryoncil aprobado por FDA
🧠 $SGMO Acuerdo AAV neurotrópico
⚡ $PRTA Avance en Parkinson
💊 $BPTH BP1001-A priorizado T2D
🔬 $NRIX Fast Track para NX-5948
🩺 $PHIO PH-762 respuestas tumorales
¡Más noticias! 📰 #Salud #biotech #stocks
www.biopharmcatalyst.com/news/2024/me...
🧬 $MESO Ryoncil aprobado por FDA
🧠 $SGMO Acuerdo AAV neurotrópico
⚡ $PRTA Avance en Parkinson
💊 $BPTH BP1001-A priorizado T2D
🔬 $NRIX Fast Track para NX-5948
🩺 $PHIO PH-762 respuestas tumorales
¡Más noticias! 📰 #Salud #biotech #stocks
www.biopharmcatalyst.com/news/2024/me...
Biotech catalyst calendars and drug pipelines • BioPharmCatalyst
Profit on the stock market by investing in biotech stocks
www.biopharmcatalyst.com
December 19, 2024 at 2:09 PM
#biotecnología hoy:
🧬 $MESO Ryoncil aprobado por FDA
🧠 $SGMO Acuerdo AAV neurotrópico
⚡ $PRTA Avance en Parkinson
💊 $BPTH BP1001-A priorizado T2D
🔬 $NRIX Fast Track para NX-5948
🩺 $PHIO PH-762 respuestas tumorales
¡Más noticias! 📰 #Salud #biotech #stocks
www.biopharmcatalyst.com/news/2024/me...
🧬 $MESO Ryoncil aprobado por FDA
🧠 $SGMO Acuerdo AAV neurotrópico
⚡ $PRTA Avance en Parkinson
💊 $BPTH BP1001-A priorizado T2D
🔬 $NRIX Fast Track para NX-5948
🩺 $PHIO PH-762 respuestas tumorales
¡Más noticias! 📰 #Salud #biotech #stocks
www.biopharmcatalyst.com/news/2024/me...
Mesoblast posted US$120m revenue in FY2026, a sevenfold jump driven by RYONCIL's US launch. Phase 3 back pain trial has completed patient enrolment.
Mesoblast posts US$120m revenue as RYONCIL ramps
Mesoblast reported sevenfold revenue growth in FY2026, driven by RYONCIL's US commercial launch, while its Phase 3 back pain trial completed patient treatment.
biotech.disruptsmedia.com
September 6, 2026 at 6:00 PM
Mesoblast posted US$120m revenue in FY2026, a sevenfold jump driven by RYONCIL's US launch. Phase 3 back pain trial has completed patient enrolment.
Mesoblast Limited (NASDAQ:MESO) Q3 Earnings: Navigating Losses with Strategic Growth in Cell Therapy www.stocks2buy.net/newsitems/me...
Mesoblast Limited (NASDAQ:MESO) Q3 Earnings: Navigating Losses with Strategic Growth in Cell Therapy
Mesoblast Limited (NASDAQ: MESO) is a global biotechnology company that develops cellular medicines for inflammatory diseases. Its main product, RYONCIL, is the first and only FDA-approved…
www.stocks2buy.net
August 27, 2026 at 4:14 PM
Mesoblast Limited (NASDAQ:MESO) Q3 Earnings: Navigating Losses with Strategic Growth in Cell Therapy www.stocks2buy.net/newsitems/me...
Mesoblast’s (#ASX: #MSB) revenue soars to US$120.3M on Ryoncil launch, cutting net loss 44%, while Phase 3 back-pain trial completes enrolment.
boldinvestors.com.au/news/mesobla...
boldinvestors.com.au/news/mesobla...
August 27, 2026 at 1:00 AM
Mesoblast’s (#ASX: #MSB) revenue soars to US$120.3M on Ryoncil launch, cutting net loss 44%, while Phase 3 back-pain trial completes enrolment.
boldinvestors.com.au/news/mesobla...
boldinvestors.com.au/news/mesobla...
🚀 A milestone for therapeutic EV research!
The FDA approval of Ryoncil signals a new chapter for cell-based therapies—and provides valuable lessons for overcoming variability and standardization challenges in MSC-EV development. 🧬
www.oaepublish.com/articles/evc...
@fhelmbacher.bsky.social
The FDA approval of Ryoncil signals a new chapter for cell-based therapies—and provides valuable lessons for overcoming variability and standardization challenges in MSC-EV development. 🧬
www.oaepublish.com/articles/evc...
@fhelmbacher.bsky.social
August 21, 2026 at 3:25 AM
🚀 A milestone for therapeutic EV research!
The FDA approval of Ryoncil signals a new chapter for cell-based therapies—and provides valuable lessons for overcoming variability and standardization challenges in MSC-EV development. 🧬
www.oaepublish.com/articles/evc...
@fhelmbacher.bsky.social
The FDA approval of Ryoncil signals a new chapter for cell-based therapies—and provides valuable lessons for overcoming variability and standardization challenges in MSC-EV development. 🧬
www.oaepublish.com/articles/evc...
@fhelmbacher.bsky.social
📢 Commentary in EVCNA!
The FDA approval of Ryoncil marks a major step toward EV therapeutics. 🌱 Discover how lessons from MSC therapy could advance standardized, clinically translatable EV-based medicines.
📖 www.oaepublish.com/articles/evc...
@labogden.bsky.social @dianvanderwaldr.bsky.social
The FDA approval of Ryoncil marks a major step toward EV therapeutics. 🌱 Discover how lessons from MSC therapy could advance standardized, clinically translatable EV-based medicines.
📖 www.oaepublish.com/articles/evc...
@labogden.bsky.social @dianvanderwaldr.bsky.social
July 29, 2026 at 3:29 AM
📢 Commentary in EVCNA!
The FDA approval of Ryoncil marks a major step toward EV therapeutics. 🌱 Discover how lessons from MSC therapy could advance standardized, clinically translatable EV-based medicines.
📖 www.oaepublish.com/articles/evc...
@labogden.bsky.social @dianvanderwaldr.bsky.social
The FDA approval of Ryoncil marks a major step toward EV therapeutics. 🌱 Discover how lessons from MSC therapy could advance standardized, clinically translatable EV-based medicines.
📖 www.oaepublish.com/articles/evc...
@labogden.bsky.social @dianvanderwaldr.bsky.social